Lenz Therapeutics, Inc.
Ophthalmic eye drop pharmaceutical for presbyopia treatment
- Sector
- Biotech
- Headquarters
- DEL MAR, CA
- Founded
- 2013
- Latest Form D
- $83.5M, Mar 2023
- Total capital
- $88.9M
- Federal grants
- None on recordNo awards found in SBIR/STTR, NIH, NSF or DoD records.
- Private capital raised
- $88.9M
- 4 Form D · last Mar 2023
- 44 months since last filing
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- 5
- 10 pending · first 2021
- Rank in peer group#269 of 1449
Capital timeline
Latest events
- Private capital raisedForm D · SEC · 4th filing$83.5M
- Private capital raisedForm D · SEC · 3rd filing$1.8M
- Private capital raisedForm D · SEC · 2nd filing$250K
- Private capital raisedForm D · SEC · 1st filing$3.4M
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Standing among 1449 peers
Line = medianBiotech · Molecule
- Granted patents#269 · top 19%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
From SEC Form D filings- Chris DimitropoulosDirectorNamed in SEC Form D filings
- Clare OzawaDirectorNamed in SEC Form D filings
- Evert SchimmelpenninkExecutive Officer, DirectorNamed in SEC Form D filings
- Frederic GuerardDirectorNamed in SEC Form D filings
- Fred GuerardDirectorNamed in SEC Form D filings
- James McCollumDirectorNamed in SEC Form D filings
Show all 8 people
- Stefan LarsonDirectorNamed in SEC Form D filings
- Zach ScheinerDirectorNamed in SEC Form D filings
What it has protected
USPTO · 5 granted of 15- PendingCompositions And Methods For The Treatment Of PresbyopiaUSPTOApplication 18465918
- PendingCompositions And Methods For The Treatment Of PresbyopiaUSPTOApplication 18239072
- PendingCompositions And Methods For The Treatment Of Eye ConditionsUSPTOApplication 17552622
Show all 15 patent records
- Compositions And Methods For The Treatment Of PresbyopiaDec 28, 2023 · Application 18465918Pending
- Compositions And Methods For The Treatment Of PresbyopiaDec 14, 2023 · Application 18239072Pending
- Compositions And Methods For The Treatment Of Eye ConditionsJun 22, 2023 · Application 17552622Pending
- Compositions And Methods For The Treatment Of PresbyopiaJun 22, 2023 · Application 18075720Pending
- Compositions And Methods For The Treatment Of PresbyopiaMay 16, 2023 · US 11,648,247Granted
- Methods For The Treatment Of MyopiaMay 31, 2022 · US 11,344,538Granted
- Compositions And Methods For The Treatment Of Eye ConditionsApr 7, 2022 · Application 17552694Pending
- Prodrugs of Quinuclidine Ring-containing Muscarinic Agonists and Compositions and Methods ThereofJan 4, 2022 · US 11,214,569Granted
- Compositions And Methods For The Treatment Of PresbyopiaNov 23, 2021 · US 11,179,327Granted
- Compositions And Methods For The Treatment Of PresbyopiaNov 23, 2021 · US 11,179,328Granted
- Compositions And Methods For Storage Stable Ophthalmic DrugsAug 19, 2021 · Application 17242398Pending
- Compositions And Methods For Storage Stable Ophthalmic DrugsApplication PCTUS2021029536Pending
- A Method Of Reducing Brow AcheApplication PCTUS2022026435Pending
- Compositions And Methods For The Treatment Of Eye ConditionsApplication PCTUS2022052922Pending
- Aceclidine Derivatives, Compositions Thereof And Methods Of Use ThereofApplication PCTUS2022050028Pending
Related companies, and why
- NEONEURON, LLCSimilar federal contract value in Biotech · null in contracts
- HotSpot TherapeuticsSimilar federal contract value in Biotech · null in contracts
- INNOVIMMUNE BIOTHERAPEUTICS HOLDING, LLCSimilar federal contract value in Biotech · null in contracts
- COMPUTCHEM LLCSimilar federal contract value in Biotech · null in contracts
- Syndax PharmaceuticalsSimilar federal contract value in Biotech · null in contracts
- Inspirna, Inc.Similar federal contract value in Biotech · null in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .